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COMMENTARY

Improving Transition
to Insulin Through
Clinical Conversations
Jana L. Wardian

Recent work suggests that how we talk to people with
diabetes can play a role in their level of engagement and
how they conceptualize diabetes management and affect
both their treatment outcomes and their motivation and
behavior (1,2). As we apply these concepts to transitioning to insulin therapy, clinicians may need to
examine how they characterize insulin and discuss it
with patients with type 2 diabetes.
Patients who perceive diabetes-related stigma are more
likely to have a negative orientation to insulin (3). Thus, it
is important to avoid using stigmatizing language and
vilifying insulin (4). Insulin is not the “bad guy” and
should not be used as a threat to reinforce the need to
change behavior before it is too late. Perhaps, unwittingly,
you have said one of the following to a patient.
• “If you don’t start exercising and lose weight, I’m going
to start you on insulin.”
• “You aren’t getting good control with the oral meds you
are taking. We have to put you on insulin.”
• “If you don’t want to be on insulin, you had better lose
weight!”

should have eaten more carrots when you were younger!”
They can just pull out their “readers” and use them to cope
with this common aging-related deﬁcit, without the fear of
being shamed by anyone.
Insulin therapy may become necessary given the progressive nature of diabetes. Consider the following
strengths-based ways of discussing insulin therapy:
• “Diabetes is a progressive disease. Your body may require insulin at some point.”
• “You’re working really hard on managing diabetes, and
I think it’s time we add insulin therapy.”
• “I think you would feel so much better if we add insulin
to your diabetes treatment. What do you think?”

The beneﬁts of insulin may include simpliﬁcation
of the medication regimen, and long-acting insulin
has a relatively low risk for hypoglycemia (9). It is
important to explain these beneﬁts of insulin therapy
to patients.
It is also important to be aware of personal attitudes and
biases concerning insulin therapy. After you have insight
about your own attitudes concerning insulin, asking
patients about their understanding of insulin may help
target speciﬁc fears and hesitancy. For example, for patients who fear injection pain, showing them how tiny the
needles are and actually helping them self-administer a
saline injection in the ofﬁce may allay their fears.
Communicating positively with patients who may need
insulin may reduce therapeutic inertia and even foster
treatment acceptance.
DUALITY OF INTEREST

Without meaning to, you may have created a barrier to future
insulin therapy (5). Most nurses and primary care clinicians
(50–55%) delay insulin until absolutely necessary, viewing
it as a last-ditch effort (6,7). However, oral or noninsulin
injectable diabetes medications may not be enough over time,
and a guilt-free door should be kept open for insulin therapy.
Discussing the progressive nature of diabetes early and
often may prepare patients for a smoother transition
should insulin therapy become the best treatment option
(8). Consider the need for reading glasses in so many
people who are over 40 years of age. No one says, “You

No potential conﬂicts of interest related to this article were
reported.
DISCLAIMER
J.L.W. is the sole author of this commentary and is responsible
for its content. The opinions expressed are those of the author
and do not reﬂect the ofﬁcial policy of the Department of
Defense or its components.
REFERENCES
1. American Association of Diabetes Educators. Speaking the
language of diabetes: language guidance for diabetes-related

Diabetes Center of Excellence, Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio, Lackland AFB, TX
Corresponding author: Jana L. Wardian, Jana.L.Wardian.ctr@mail.mil
https://doi.org/10.2337/cd19-0089
©2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not
for proﬁt, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
VOLUME 38, NUMBER 3, SUMMER 2020

28 5

COMMENTARY
research, education, and publications. Available from https://
www.diabeteseducator.org/practice/practice-tools/app-resources/
diabetes-language-paper. Accessed 10 February 2020

6. Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and
intensiﬁcation in the UK: a focused literature review. Prim Care
Diabetes 2017;11:3–12

2. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of
language in diabetes care and education. Diabetes Care 2017;
40:1790–1799

7. Peyrot M, Rubin RR, Lauritzen T, et al.; International DAWN
Advisory Panel. Resistance to insulin therapy among patients and
providers: results of the cross-national Diabetes Attitudes,
Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:
2673–2679

3. Holmes-Truscott E, Browne JL, Ventura AD, Pouwer F, Speight
J. Diabetes stigma is associated with negative treatment
appraisals among adults with insulin-treated type 2 diabetes:
results from the second Diabetes MILES–Australia (MILES-2)
survey. Diabet Med 2018;35:658–662
4. Liu NF, Brown AS, Folias AE, et al. Stigma in people with type 1
or type 2 diabetes. Clin Diabetes 2017;35:27–34
5. Meece J. Dispelling myths and removing barriers about insulin
in type 2 diabetes. Diabetes Educ 2006;32(Suppl.):9S–18S

2 86

8. Polinski JM, Smith BF, Curtis BH, et al. Barriers to insulin
progression among patients with type 2 diabetes: a systematic
review. Diabetes Educ 2013;39:53–65
9. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to
insulin in type 2 diabetes: family physicians’ misconception of
patients’ fears contributes to existing barriers. J Diabetes
Complications 2007;21:220–226

CLINICAL.DIABETESJOURNALS.ORG

